Treatment with the tubulin polymerization inhibitor combrestatin altered the shape of BMECs, depleting VCAM-1 and VE-cadherin in AML cells, leading to increased peripheral blood cycling of AML cells. Here, CDH5 is linked to acute myeloid leukemia.